Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
FIGO Stage III-IV: later-stage trial registry
A small indexed set (2 trials) with no open enrollment listed right now.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count
FIGO Stage III-IV: 2 US clinical trials tracked, none currently recruiting.
FIGO Stage III-IV is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 2 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is pharmaand, running 1 of these trials.
Enrollment posture brief
Registry condition figo-stage-iii-iv
OPEN 0 | RECR 0% | LATE 2 | EARLY 0 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
FIGO Stage III-IV has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for FIGO Stage III-IV on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
FIGO Stage III-IV is recruiting below its size-band peers.
0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
2 total, page 1 of 1
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
pharmaand
NCT03522246
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
AstraZeneca
NCT01844986
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on FIGO Stage III-IV records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on FIGO Stage III-IV trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this FIGO Stage III-IV page
2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No FIGO Stage III-IV trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- pharmaand sponsors the most FIGO Stage III-IV trials on record, review their full trial history before evaluating a specific study. See pharmaand's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This FIGO Stage III-IV condition card totals 2 registered trials; most-linked intervention Placebo IV Infusion; top US site state Georgia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.